Jinsil Seong
연세대학교 · Medicine
이 교수의 연구실은 간세포생식성암(HCC)의 정밀 치료 전략 개발에 초점을 맞추고 있습니다. 특히 방사선 치료와 면역치료를 융합한 '면역방사선요법'의 임상적 유효성과 최적 병용 요법 기반의 다학제 치료 전략을 연구하고 있으며, 간암의 병행 치료에서 방사선의 병용 효과와 최적 용량·부위 설정에 대한 임상적 근거를 제시하고 있습니다. 고도로 정밀한 방사선 치료 기술의 발전을 바탕으로, 간기능이 손상된 환자에게도 안전하고 효과적인 치료 옵션을 모색하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
In conclusion, radiotherapy provides effective palliation for patients with painful bone metastases from HCC during the substantial median survival time.
The combination of anti-PD-L1 and radiation significantly improved the antitumor effect shown in tumor growth delay as well as in survival, supporting a novel combination strategy of immunoradiotherapy in HCC.
The equivalent RT dose ˃45 Gy, given in combination with other treatments, provided better PVTT control and OS. The optimal RT volume is suggested for either PVTT + primary or PVTT only. Taken together, multimodal treatment with equivalent RT dose higher than 45 Gy is recommended for patients with HCC and PVTT.
Radiotherapy has been used to treat advanced HCC in various modes, but mostly as a salvage treatment. Although this study was retrospective, it indicates that radiotherapy is a quite effective modality for HCC patients.
Hepatocellular carcinoma (HCC) is one of the most critical global health issues. With frequent association of viral liver disease, HCC is highly complex, harboring both cancer and chronic liver disease. The tumor stage and underlying liver function are both major determinants of the treatment selection as well as prognosis in HCC patients, thus allowing no more than a 20% chance for potentially curative therapies. Radiotherapy technology has been evolved remarkably during the past decade, and ra
